The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).
 
Andrew Weickhardt
Honoraria - Eisai; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Pfizer; Telix Pharmaceuticals
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Ipsen; Merck Sharp & Dohme
 
Farshad Foroudi
No Relationships to Disclose
 
Nathan Lawrentschuk
No Relationships to Disclose
 
Jing Xie
No Relationships to Disclose
 
Yi-An Ko
No Relationships to Disclose
 
Mark Sidhom
No Relationships to Disclose
 
Abhijit Pal
Consulting or Advisory Role - Novotech
Travel, Accommodations, Expenses - MSD
Other Relationship - AstraZeneca; Pfizer
 
Peter Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Genentech (Inst); InhibRx (Inst); InhibRx (Inst); Janssen-Cilag (Inst); MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)
 
Alison Zhang
Honoraria - Astellas Pharma; AstraZeneca; Bayer; MSD Oncology; Mundipharma; Pfizer (Inst)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Janssen Oncology; Merck; Merck Sharp & Dohme; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; MSD Oncology
 
Siobhan Ng
No Relationships to Disclose
 
Colin Tang
No Relationships to Disclose
 
Elizabeth Hovey
No Relationships to Disclose
 
Colin Chen
No Relationships to Disclose
 
George Hruby
No Relationships to Disclose
 
Alexander Guminski
No Relationships to Disclose
 
Samantha Oakes
No Relationships to Disclose
 
Ciara Conduit
No Relationships to Disclose
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Dickon Hayne
No Relationships to Disclose
 
Australia and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose